Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 recombinant protein vaccine with adjuvants in healthy adults
NCT04537208Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of monovalent [B.1.351] CoV2 preS dTM-AS03 in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started Sep 2020; status: completed.
02
Drugs
monovalent [B.1.351] CoV2 preS dTM-AS03
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04537208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537208.